Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

Moderna shares surge as Merck-partnered melanoma vaccine cuts recurrence in large trial  Reuters

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Drugmaker’s cancer shot developed with Merck delivers positive outcome in late-stage trial

Landmark vaccine stops cancer returning in trial  The Times

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing skin cancer from returning or spreading in a study of melanoma patients.

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial  CNN

The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed